Particle.news

Download on the App Store

CCPA Fines VLCC Rs 3 Lakh for Misleading CoolSculpting Weight-Loss Claims

The regulator ordered prominent disclaimers limiting claims to US‑FDA‑approved localized fat reduction after citing small, non‑Indian clinical evidence.

Image

Overview

  • VLCC must state in advertisements and consent forms: “The CoolSculpting Procedure is used for treatment of the focal fat deposits and not weight loss.”
  • CCPA said VLCC’s promotions promised outcomes such as “Lose up to 600g and 7 cm in 1 session” and “Drop 1 size in 1 session permanently,” implying guaranteed results.
  • The authority clarified that CoolSculpting is cleared only for reducing fat bulges in specific body areas and for individuals with a BMI of 30 or less, not for overall weight loss.
  • CCPA noted the clinical evidence submitted to the US‑FDA involved 57 participants without Indian or Asian representation and that there is no US‑FDA endorsement specific to India.
  • The watchdog earlier fined Kaya Rs 3 lakh for similar ads and warned clinics and service providers that further violations will lead to penalties, removal of misleading ads, and legal action.